The role of vasopressin in cardiorespiratory arrest and pulmonary hypertension

QJM: An International Journal of Medicine

Volumn 99, Issue 3, 2006, Pages 127-133

  Smith, A M ^a,b   Elliot, C M ^b   Kiely, D G ^b   Channer, Kevin S ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ARGIPRESSIN; DIGOXIN; DIURETIC AGENT; OXYGEN; TERLIPRESSIN; VASOPRESSIN; WARFARIN;

ASYSTOLE; BRAIN BLOOD FLOW; CARDIOPULMONARY INSUFFICIENCY; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; HEART ARREST; HEART VENTRICLE FIBRILLATION; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; HYPOXIA; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG CIRCULATION; MORTALITY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

EID: 33645295749     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl009     Document Type: Review

References (36)

1. Lindner KH, Prengel AW, Brinkmann A, Strohmenger HU, Lindner IM, Lurie KG. Vasopressin administration in refractory cardiac arrest. Ann Intern Med 1996; 124:1061-4.
2. Wenzel V, Krismer AC, Arntz HR, Sitter H, Stadlbauer KH, Lindner KH, et al. A comparison of vasopressin and epinephrine for out-of-hospital cardiopulmonary resuscitation. N Engl J Med 2004; 350:105-13.
3. Newman JH, Fanburg BL, Archer SL, Badesch DB, Barst RJ, Garcia JGN, et al. Pulmonary arterial hypertension - Future directions - Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop. Circulation 2004; 109:2947-52.
4. Kam PCA, Williams S, Yoong FFY. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004; 59:993-1001.
5. Thibonnier M, Conorty DM, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R. The human V3 pituitary vasopressin receptor: Ligand binding profile and density-dependant signalling pathways. Endocrinology 1997; 138:4109-22.
6. Oliver H, SChafer E. On the physiological action of extracts of the pituitary body and certain other glandular organs. J Physiol 1895; 18:277-9.
7. Du Vigneaud V, Gash DT, Katsoyaniss PG. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J Am Chem Soc 1954; 76:4751-2.
8. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after cardiopulmonary-resuscitation. Anesthesiology 1992; 77:662-68.
9. Lindner KH, Prengel AW, Pfenninger EG, Lindner IM, Strohmenger HU, Georgieff M, et al. Vasopressin improves vital organ blood-flow during closed-chest cardiopulmonary-resuscitation in pigs. Circulation 1995; 91:215-21.
10. Prengel AW, Lindner KH, Keller A. Cerebral oxygenation during cardiopulmonary resuscitation with epinephrine and vasopressin in pigs. Stroke 1996; 27:1241-7.
11. Wenzel V, Lindner KH, Krismer AC, Miller EA, Voelckel WG, Lingnau W. Repeated administration of vasopressin but not epinephrine maintains coronary perfusion pressure after early and late administration during prolonged cardiopulmonary resuscitation in pigs. Circulation 1999; 99:1379-84.
12. Lindner KH, Dirks B, Strohmenger HU, Prengel AW, Lindner IM, Lurie KG. Randomised comparison of epinephrine and vasopressin in patients with out-of-hospital ventricular fibrillation. Lancet 1997; 349:535-7.
13. Stiell IG, Hebert PC, Wells GA, Vandemheen KL, Tang ASL, Higginson LAJ, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: A randomised controlled trial. Lancet 2001; 358:105-9.
14. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for the Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2000; 8(suppl):I129-35.
15. The European Resuscitation Council. Guidelines 2000 for the Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Resuscitation 2000; 46:155-62.
16. Gibbs JSR, Higenbottam TW, Black C, Corris PA, Haworth SG, McNeil K, et al. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001; 86:11-13.
17. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5-128.
18. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary Pulmonary Hypertension - a National Prospective-Study. Ann Intern Med 1987; 107:216-23.
19. Dalonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary-hypertension - Results from a National Prospective Registry. Ann Intern Med 1991; 115:343-9.
20. Hoeper MM, Galie N, Murali S, Olschewski H, Rubenfire M, Robbins IM, et al. Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:341-4.
21. Russ RD, Walker BR. Role of nitric-oxide in vasopressinergic pulmonary vasodilatation. Am J Physiol 1992; 262:H743-7.
22. Eichinger MR, Russ RD, Walker BR. Potassium channels are not involved in vasopressin-induced vasodilation in the rat lung. Am J Physiol 1994; 266:H491-5.
23. Walker BR, Haynes J, Wang HL, Voelkel NF. Vasopressin-induced pulmonary vasodilation in rats. Am J Physiol 1989; 257:H415-22.
24. Jin HK, Yang RH, Chen YF, Jackson R, Oparil S. Arginine vasopressin lowers pulmonary arterial-pressure in rats adapted to chronic hypoxia. Am J Med Sci 1987; 293:274-8.
25. Jin HK, Yang RH, Chen YF, Thornton RM, Jackson RM, Oparil S. Hemodynamic-effects of arginine vasopressin in rats adapted to chronic hypoxia. J Appl Physiol 1989; 66:151-60.
26. Jin HK, Chen YF, Yang RH, McKenna TM, Jackson RM, Oparil S. Vasopressin lowers pulmonary-artery pressure in hypoxic rats by releasing atrial natriuretic peptide. Am J Med Sci 1989; 298:227-36.
27. Wallace AW, Tunin CM, Shoukas AA. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 1989; 257:H1228-34.
28. Nyhan DP, Geller HS, Goll HM, Murray PA. Pulmonary vasoactive effects of exogenous and endogenous AVp in conscious dogs. Am J Physiol 1986; 251:1009-16.
29. Leather HA, Segers P, Berends N, Vandermeersch E, Wouters PF. Effects of vasopressin on right ventricular function in an experimental model of acute pulmonary hypertension. Crit Care Med 2002; 30:2548-2552.
30. Evora PRB, Pearson PJ, Schaff HV. Arginine Vasopressin induces endothelium-dependent vasodilatation of the pulmonary-artery. V-receptor-mediated production of nitric-oxide. Chest 1993; 103:1241-5.
31. Sai Y, Okamura T, Amakata Y, Toda N. Comparison of responses of canine pulmonary-artery and vein to angiotensin-II, bradykinin and vasopressin. Eur J Pharmacol 1995; 282:235-41.
32. Nelson RA, May LG, Bennett A, Kobayashi M, Gregory R. Comparison of the effects of pressor and depressor agents and influences on pulmonary and systemic pressures of normotensive and hypertensioe subjects. Am Heart J 1955; 50:172-87.
33. Ribot S, Green H, Small MJ, Abramowitz S. Cardiovascular effects of vasopressin. Am J Med Sci 1961; 242:612-19.
34. Segel N, Bayley TJ, Paton A, Dykes PW, Bishop JM. The effects of synthetic vasopressin and angiotensin on the circulation in cirrhosis of the liver. Clin Sci 1963; 25:43-55.
35. Mols P, Hallemans R, Vankuyk M, Melot C, Lejeune P, Ham H, et al. Hemodynamic-effects of vasopressin, alone and in combination with nitroprusside, in patients with liver-cirrhosis and portal-hypertension. Ann Surg 1984; 199:176-81.
36. Altintas E, Akkus N, Gen R, Helvaci MR, Sezgin O, Oguz D. Effects of terlipressin on systolic pulmonary artery pressure in patients with liver cirrhosis: An echocardiographic assessment. World J Gastroenterol 2004; 10:2278-80.